Naloxone-reversible monocyte dysfunction in patients with chronic fatigue syndrome.
Prieto, J, Subirá, M L, Castilla, A et al. · Scandinavian journal of immunology · 1989 · DOI
Quick Summary
Researchers examined immune cells called monocytes in 35 ME/CFS patients and 25 healthy people. They found that most ME/CFS patients had monocytes that weren't working properly, but these cells improved dramatically when treated with naloxone, a drug that blocks opioid effects. This suggests that the body's natural opioid-like chemicals may be overactive in ME/CFS and could be damaging immune function.
Why It Matters
This study proposes a novel mechanism for ME/CFS pathology—dysregulated endogenous opioid activity—that could explain immune dysfunction central to the disease. If endogenous opioids are indeed pathogenic, this opens therapeutic avenues such as opioid antagonists, potentially offering a targeted treatment strategy rather than symptom management alone.
Observed Findings
85% of ME/CFS patients showed reduced monocyte vimentin filaments, low phagocytosis index, and decreased HLA-DR antigen expression compared to controls.
Monocyte function values increased dramatically after naloxone incubation in patient samples.
Reduced expression of Fc receptors for IgG and C3b complement receptors on monocytes in patients.
Inferred Conclusions
Increased endogenous opioid activity, acting through classical opioid receptors, suppresses monocyte function in a majority of ME/CFS patients.
Opioid peptides represent a previously unrecognized immunomodulatory pathway in ME/CFS pathogenesis.
Opioid antagonism may reverse immune dysfunction in ME/CFS.
Remaining Questions
What is the source of excess endogenous opioid activity (central nervous system, peripheral tissues, or both)?
Are endogenous opioid levels elevated in blood and cerebrospinal fluid of CFS patients, and do these correlate with disease severity?
Would long-term opioid antagonist treatment improve clinical outcomes in CFS patients?
What This Study Does Not Prove
This study does not prove that elevated opioids directly cause ME/CFS, only that opioid-mediated dysfunction exists in monocytes from most patients studied. It does not measure actual endogenous opioid levels in the blood or tissues, so the source and magnitude of opioid excess remains uncharacterized. Cross-sectional design prevents determining whether opioid dysfunction precedes disease onset or results from it.